-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2507 Acute Pulmonary Embolism and Cancer: Clinical Features, Management and Short-Term Course. Findings from the COPE Study

Program: Oral and Poster Abstracts
Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Bleeding and Clotting, thromboembolism, Diseases
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Cecilia Becattini, MD1,2*, Ludovica Anna Cimini, MD3*, Giorgio Bassanelli, MD4*, Aldo P Maggioni, MD5*, Fulvio Pomero, MD6*, Ilaria Lobascio, MD7*, Daniela P Pomata, MD8*, Maria P Ruggeri, MD9*, Beniamino Zalunardo, MD10*, Anna Novelli, MD11*, Giancarlo Agnelli, MD1*, Lucio Gonzini, MD12* and Michele M Gulizia, MD13*

1Internal Vascular and Emergency Medicine Stroke Unit, University of Perugia, Perugia, Italy
2University of Perugia, Perugia, ITA
3Internal, Vascular and Emergency Medicine– Stroke Unit, University of Perugia, Perugia, Italy
4Department of Cardiology, Ospedale Alessandro Manzoni, Lecco, Italy
5ANMCO Research Center, Heart Care Foundation, Florence, Italy
6Division of Internal Medicine, Michele and Pietro Ferrero Hospital, Verduno, Italy
7UOC Cardiologia, Ospedale Civile, Arzignano, Italy
8UOC Medicina d'Urgenza e PS, Ospedale Policlinico S. Orsola-Malpighi, Bologna, Italy
9U.O.C. Medicina d’Urgenza e Pronto Soccorso, AO San Giovanni Addolorata, Roma, Italy
10UOC Angiologia, P.O. Castelfranco Veneto, Castelfranco Veneto, Italy
11PS e Medicina d'Urgenza, Ospedali Riuniti, Livorno, Italy
12ANMCO Research Center, Heart Care Foundation, Firenze, Italy
13Division of Cardiology, Garibaldi-Nesima Hospital, Catania, Italy

Background About 20% of patients with venous thromboembolism (VTE) have concomitant cancer. The aim of this analysis is to describe the clinical features, management and short-term course in patients with acute pulmonary embolism (PE) included in the COPE Registry, by cancer status.

Methods COPE is a prospective, multicentre study of adult patients with acute, symptomatic, objectively diagnosed PE. Patients were classified into three groups by cancer status: with active cancer, with history of cancer or without cancer. Active cancer was defined in case of diagnosis performed in the 6 months before study inclusion, metastatic disease or ongoing anticancer treatment. Patients with data unavailable on presence/absence of cancer were excluded from this analysis.

Results Data on cancer were available in 4956 COPE patients (95.1%); 832 (16.8%), 464 (9.4%) and 3660 (73.8%) patients were classified as having active cancer, history of cancer or no cancer, respectively. Among patients with active cancer, urogenital, gastrointestinal and lung cancer were the most common, accounting for about 20% each; at diagnosis of PE, 419 patients (57.6%) had metastatic disease, 364 (46.0%) and 128 (16.2%) were receiving anticancer agents or radiotherapy. Different prevalence of comorbidities and risk factors for PE was observed among patients with active cancer, history of cancer or no cancer. At discharge, a DOAC was given in 43.1%, 78.8% and 82.0% of patients with active cancer, history of cancer and no cancer, respectively. Despite the proportion of high and intermediate-high risk patients was similar, death in-hospital and at 30 days were higher in patients with active cancer compared to patients with history of cancer and no cancer (7.9 vs 4.3 vs 2.2% and 13.8 vs 5.2 vs 2.6%, respectively) (Figure). Similar findings were observed concerning the incidence of major bleeding. In patients with active cancer, death at 30 days was more frequent in those with lung cancer or metastatic disease and major bleeding in those with gastrointestinal, hematological or brain cancer (Table). Among patients with active cancer, death due to cancer, PE or major bleeding occurred in 28, 18 and 5 during the hospital stay and in 66, 19 and 6 at 30 days. The analysis for predictors of death at 30 days in patients with and without active cancer will be available for presentation by the ASH Congress 2022.

Conclusions Among patients with acute PE, those with active cancer, history of cancer and no cancer have peculiar features, different risk for death or major bleeding in hospital and at 30 days. Our findings may challenge clinical practice and inform future studies.

Disclosures: Becattini: Bayer AG: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria.

*signifies non-member of ASH